METTL3 and neoplasm: For patients with advanced-stage disease (n = 70), a high level of METTL3 in tumour cells was dramatically correlated with decreased DFS (P < 0.001, Fig. 4a) and OS (P < 0.001, Fig. 4b), and a high level of METTL3 in tumour-infiltrating immune cells was negatively correlated with DFS (P = 0.004, Fig. 4c) and OS (P < 0.001, Fig. 4d); the increased number of CD33+ MDSCs was dramatically correlated with poor DFS (P < 0.001, Fig. 4e) and OS (P < 0.001, Fig. 4f).